CSIMarket
 

C4 Therapeutics Inc   (CCCC)
Other Ticker:  
 

C4 Therapeutics Inc 's

Competitiveness


 

CCCC Sales vs. its Competitors Q4 2023







Revenue Growth Comparisons




Net Income Comparison




<<  CCCC Stock Performance Comparisons



*Market share is calculated based on total revenue.

  News about C4 Therapeutics Inc Contracts

Unleashing the Power of BiDAC Degraders: C4 Therapeutics Shakes Up Cancer Treatment Landscape

C4 Therapeutics Makes a Splash with Groundbreaking Preclinical Data on BiDAC DegradersAt the American Association for Cancer Research Annual Meeting 2024, C4 Therapeutics unveiled exciting new preclinical data showcasing the highly selective orally bioavailable BiDAC Degraders. This revolutionary technology has the potential to revolutionize cancer treatment by targeting specific proteins for degradation, promising better outcomes for patients.One of the most significant findings from C4 Therapeutics' presentation was the demonstration of CFT1946's promising activity as a single agent and in combination therapies. In preclinical models, CFT1946 exhibited remarkable efficacy in BRAF V600X Melanoma, Colorectal...

C4 Therapeutics and Merck KGaA Forge Strategic Alliance in Oncology Research

In a significant development that highlights the increasing importance of targeted protein degradation in oncology research, C4 Therapeutics (C4T) has announced a strategic discovery research collaboration with Merck KGaA, Darmstadt, Germany. This collaboration aims to combat critical oncogenic proteins while leveraging the strengths of two specific targeted protein degraders from C4T's internal discovery pipeline. This article explores the facts surrounding this partnership and assesses its potential impact on C4 Therapeutics.Facts:1. C4 Therapeutics announces a discovery research collaboration with Merck KGaA, Darmstadt, Germany.2. The collaboration focuses on combating critical oncogenic proteins, which a...

Steering The Course of Biopharmaceutical Future: C4 Therapeutics Tackles Targeted Protein Degradation

C4 Therapeutics, a frontrunner in the biopharmaceutical landscape, has recently revealed its strategic plan for 2024, outlining a keen focus on the development and progression of targeted protein degradation (TPD) medicines. C4's dynamic shift towards this avant-garde field of biomedical science not only displays its innovative approach towards disease treatment but also predicts an impressive evolution for the larger pharmaceutical sector.Currently, the company is investing its resources and research prowess into Phase 1 Dose Escalation Trials of CFT7455 and CFT1946, novel compounds that may redefine the way we treat diseases in the not-too-distant future. The company has also reported that it expects multi...

C4 Therapeutics Unveils Promising Data on CFT7455 for Relapsed/Refractory Multiple Myeloma, Reports Revenue Growth in Q3 2023



C4 Therapeutics, Inc. (C4T), a clinical-stage biopharmaceutical company pioneering targeted protein degradation science, recently announced the presentation of new Phase 1 dose escalation data for relapsed/refractory multiple myeloma. The data was from the ongoing Phase 1/2 clinical trial of CFT7455, a MonoDAC degrader of IKZF1/3, and holds significant potential for the treatment of this challenging blood cancer. Additionally, the company reported a rise in revenue during the third quarter of 2023, showcasing its growth trajectory compared to competitors in the market.
Overview of C4 Therapeutics' Webcast:
C4 Therapeutics will host a webcast on December 12, 2023, at 4:30 PM ET, focused on p...





Who are C4 Therapeutics Inc 's Competitors?





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com